Trial · NCT02925234
The Drug Rediscovery Protocol (DRUP Trial)
NCT02925234, Phase 2, Recruiting, The Netherlands Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Drug Rediscovery Protocol (DRUP Trial). Trials, record NCT02925234. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02925234
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Drug Rediscovery Protocol (DRUP Trial)
- NCT number
- NCT02925234
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 1,550 participants, estimated
- Lead sponsor
- The Netherlands Cancer Institute
- Conditions
- Cancer, Tumors, Neoplasm, Neoplasia
- Interventions
Panitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib
- First posted
- 2016-10-05
- Last updated
- 2024-01-24
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of patients that are treated based on their molecular tumor profile | 6 months after treatment initiation (estimated average) | Primary outcome measure 1 is the percentage of submitted patients, that can be treated based on their molecular tumor profile within the context of this protocol. |
| Primary | Objective tumor response | 6 months after treatment initiation (estimated average) | Primary outcome measure 2 is the proportion of study participants with an objective tumor response upon study treatment.. |
| Primary | Stable disease | 6 months after treatment initiation (estimated average) | Primary outcome measure 3 is the proportion of study participants that has stable disease (SD) during study treatment. |
| Primary | Treatment-related grade≥3 and serious adverse events | 6 months after treatment initiation (estimated average) | Primary outcome measure 4 is the proportion of patients that experience treatment-related grade≥3 and /or serious adverse events. |
| Secondary | Progression-free survival | Up to 1 year after study completion | |
| Secondary | Overall survival | Up to 1 year after study completion | |
| Secondary | Duration of treatment on study (time on drug) | 6 months after treatment initiation (estimated average) | |
| Other | Concordance between pre-treatment and historic mutational tumor profile | 2 months after treatment initiation (estimated average) | Sequencing results of fresh pre-treatment biopsies will be available within 2 months after treatment initiation. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02925234
GET https://conductscience.org/api/trials/v1/NCT02925234/registered